vs
Side-by-side financial comparison of Northfield Bancorp, Inc. (NFBK) and ARS Pharmaceuticals, Inc. (SPRY). Click either name above to swap in a different company.
Northfield Bancorp, Inc. is the larger business by last-quarter revenue ($41.3M vs $28.1M, roughly 1.5× ARS Pharmaceuticals, Inc.). ARS Pharmaceuticals, Inc. runs the higher net margin — -147.1% vs -1545.5%, a 1398.4% gap on every dollar of revenue. On growth, Northfield Bancorp, Inc. posted the faster year-over-year revenue change (12.7% vs -67.6%).
Northfield Bancorp, Inc. is a regional bank holding company based in the United States, operating primarily across the U.S. Northeast region. It provides a full range of personal and commercial banking services including deposit accounts, mortgage loans, commercial lending, and wealth management solutions for retail consumers, small to medium-sized businesses and local community clients.
ARS Pharmaceuticals, Inc. is a late-stage biopharmaceutical firm specializing in the development and commercialization of novel therapies for severe allergic reactions, most notably needle-free epinephrine delivery solutions for anaphylaxis. It primarily operates in the North American market, catering to both pediatric and adult patient groups at risk of life-threatening allergic responses.
NFBK vs SPRY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $41.3M | $28.1M |
| Net Profit | $-27.4M | $-41.3M |
| Gross Margin | — | — |
| Operating Margin | -1263.3% | -147.6% |
| Net Margin | -1545.5% | -147.1% |
| Revenue YoY | 12.7% | -67.6% |
| Net Profit YoY | -343.6% | -182.8% |
| EPS (diluted) | $-0.68 | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $41.3M | $28.1M | ||
| Q3 25 | $39.2M | $32.5M | ||
| Q2 25 | $38.9M | $15.7M | ||
| Q1 25 | $34.8M | $8.0M | ||
| Q4 24 | $36.7M | $86.6M | ||
| Q3 24 | $31.8M | $2.1M | ||
| Q2 24 | $31.5M | $500.0K | ||
| Q1 24 | $31.3M | $0 |
| Q4 25 | $-27.4M | $-41.3M | ||
| Q3 25 | $10.8M | $-51.2M | ||
| Q2 25 | $9.6M | $-44.9M | ||
| Q1 25 | $7.9M | $-33.9M | ||
| Q4 24 | $11.3M | $49.9M | ||
| Q3 24 | $6.5M | $-19.1M | ||
| Q2 24 | $6.0M | $-12.5M | ||
| Q1 24 | $6.2M | $-10.3M |
| Q4 25 | -1263.3% | -147.6% | ||
| Q3 25 | 37.7% | -163.7% | ||
| Q2 25 | 35.6% | -302.9% | ||
| Q1 25 | 31.0% | -466.3% | ||
| Q4 24 | 38.0% | 54.5% | ||
| Q3 24 | 27.9% | -1051.6% | ||
| Q2 24 | 29.1% | -3068.0% | ||
| Q1 24 | 27.2% | — |
| Q4 25 | -1545.5% | -147.1% | ||
| Q3 25 | 27.4% | -157.4% | ||
| Q2 25 | 24.6% | -285.6% | ||
| Q1 25 | 22.6% | -425.7% | ||
| Q4 24 | 30.7% | 57.7% | ||
| Q3 24 | 20.5% | -925.0% | ||
| Q2 24 | 18.9% | -2503.2% | ||
| Q1 24 | 19.9% | — |
| Q4 25 | $-0.68 | $-0.41 | ||
| Q3 25 | $0.27 | $-0.52 | ||
| Q2 25 | $0.24 | $-0.46 | ||
| Q1 25 | $0.19 | $-0.35 | ||
| Q4 24 | $0.27 | $0.52 | ||
| Q3 24 | $0.16 | $-0.20 | ||
| Q2 24 | $0.14 | $-0.13 | ||
| Q1 24 | $0.15 | $-0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $164.0M | $245.0M |
| Total DebtLower is stronger | — | $96.4M |
| Stockholders' EquityBook value | $690.1M | $114.3M |
| Total Assets | $5.8B | $327.7M |
| Debt / EquityLower = less leverage | — | 0.84× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $164.0M | $245.0M | ||
| Q3 25 | $131.7M | $288.2M | ||
| Q2 25 | $97.6M | $240.1M | ||
| Q1 25 | $101.7M | $275.7M | ||
| Q4 24 | $167.7M | $314.0M | ||
| Q3 24 | $232.9M | $204.6M | ||
| Q2 24 | $153.5M | $218.7M | ||
| Q1 24 | $238.8M | $223.6M |
| Q4 25 | — | $96.4M | ||
| Q3 25 | — | $96.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $666.4M | $0 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $690.1M | $114.3M | ||
| Q3 25 | $719.6M | $147.7M | ||
| Q2 25 | $710.3M | $192.3M | ||
| Q1 25 | $711.1M | $229.0M | ||
| Q4 24 | $704.7M | $256.8M | ||
| Q3 24 | $699.6M | $201.0M | ||
| Q2 24 | $693.0M | $215.2M | ||
| Q1 24 | $698.4M | $223.9M |
| Q4 25 | $5.8B | $327.7M | ||
| Q3 25 | $5.7B | $372.8M | ||
| Q2 25 | $5.7B | $313.5M | ||
| Q1 25 | $5.7B | $327.3M | ||
| Q4 24 | $5.7B | $351.2M | ||
| Q3 24 | $5.7B | $217.6M | ||
| Q2 24 | $5.7B | $222.0M | ||
| Q1 24 | $5.9B | $227.6M |
| Q4 25 | — | 0.84× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.95× | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $53.7M | $-43.5M |
| Free Cash FlowOCF − Capex | $52.5M | — |
| FCF MarginFCF / Revenue | 127.1% | — |
| Capex IntensityCapex / Revenue | 2.8% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $89.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $53.7M | $-43.5M | ||
| Q3 25 | $13.9M | $-47.0M | ||
| Q2 25 | $14.1M | $-39.6M | ||
| Q1 25 | $9.4M | $-40.7M | ||
| Q4 24 | $31.1M | $42.0M | ||
| Q3 24 | $14.0M | $-14.5M | ||
| Q2 24 | $6.9M | $-7.3M | ||
| Q1 24 | $4.2M | $-6.7M |
| Q4 25 | $52.5M | — | ||
| Q3 25 | $13.6M | $-47.2M | ||
| Q2 25 | $13.9M | $-39.6M | ||
| Q1 25 | $9.2M | $-40.8M | ||
| Q4 24 | $30.0M | $41.7M | ||
| Q3 24 | $13.7M | $-14.6M | ||
| Q2 24 | $6.7M | $-7.3M | ||
| Q1 24 | $3.8M | $-6.8M |
| Q4 25 | 127.1% | — | ||
| Q3 25 | 34.6% | -145.4% | ||
| Q2 25 | 35.7% | -252.2% | ||
| Q1 25 | 26.3% | -512.1% | ||
| Q4 24 | 81.6% | 48.2% | ||
| Q3 24 | 43.2% | -706.3% | ||
| Q2 24 | 21.1% | -1463.4% | ||
| Q1 24 | 12.1% | — |
| Q4 25 | 2.8% | 0.0% | ||
| Q3 25 | 0.8% | 0.6% | ||
| Q2 25 | 0.6% | 0.3% | ||
| Q1 25 | 0.7% | 1.1% | ||
| Q4 24 | 3.1% | 0.3% | ||
| Q3 24 | 0.7% | 6.8% | ||
| Q2 24 | 0.8% | 7.6% | ||
| Q1 24 | 1.4% | — |
| Q4 25 | — | — | ||
| Q3 25 | 1.29× | — | ||
| Q2 25 | 1.48× | — | ||
| Q1 25 | 1.20× | — | ||
| Q4 24 | 2.76× | 0.84× | ||
| Q3 24 | 2.14× | — | ||
| Q2 24 | 1.16× | — | ||
| Q1 24 | 0.68× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NFBK
Segment breakdown not available.
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
